MDPI and ACS Style
Graham, D.Y.; Naser, S.A.; Borody, T.; Hebzda, Z.; Sarles, H.; Levenson, S.; Hardi, R.; Arłukowicz, T.; Svorcan, P.; Fathi, R.;
et al. Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease. Antibiotics 2024, 13, 694.
https://doi.org/10.3390/antibiotics13080694
AMA Style
Graham DY, Naser SA, Borody T, Hebzda Z, Sarles H, Levenson S, Hardi R, Arłukowicz T, Svorcan P, Fathi R,
et al. Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease. Antibiotics. 2024; 13(8):694.
https://doi.org/10.3390/antibiotics13080694
Chicago/Turabian Style
Graham, David Y., Saleh A. Naser, Thomas Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi,
and et al. 2024. "Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease" Antibiotics 13, no. 8: 694.
https://doi.org/10.3390/antibiotics13080694